{"id":817365,"date":"2025-02-25T07:26:15","date_gmt":"2025-02-25T12:26:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/"},"modified":"2025-02-25T07:26:15","modified_gmt":"2025-02-25T12:26:15","slug":"marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/","title":{"rendered":"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference"},"content":{"rendered":"
\n

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc.<\/a> (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd<\/sup> Annual Cell Therapy Virtual Conference. This virtual investor event will be held on February 25, 2025.<\/p>\n

Dr. Vera will present an overview of Marker\u2019s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET).<\/p>\n

\n Details of the presentation are as follows:<\/strong>\n <\/p>\n\n\n\n\n\n
\n \u00a0Event:<\/strong>\n <\/td>\n\u00a0H.C. Wainwright 3rd<\/sup> Annual Cell Therapy Virtual Conference<\/td>\n<\/tr>\n
\n \u00a0Date:\u00a0<\/strong>\n <\/td>\n\u00a0February 25, 2025, at 3:30 PM ET<\/td>\n<\/tr>\n
\n \u00a0Location:<\/strong>\n <\/td>\n\u00a0Virtual Meeting<\/td>\n<\/tr>\n
\n \u00a0Registration:<\/strong>\n <\/td>\n\u00a0https:\/\/hcwevents.com\/celltherapy\/<\/a><\/td>\n<\/tr>\n<\/table>\n

\n
Registered participants will have access to the presentation through the event portal on the day of the event.<\/p>\n

\n About Marker Therapeutics, Inc.<\/strong>
\n
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company\u2019s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker\u2019s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker\u2019s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.<\/p>\n

To receive future press releases via email, please visit: https:\/\/www.markertherapeutics.com\/email-alerts<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company\u2019s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are \u201cforward-looking statements.\u201d Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company\u2019s most recent Form 10-K, 10-Q and other\u00a0SEC\u00a0filings which are available through EDGAR at\u00a0WWW.SEC.GOV<\/a>. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.<\/p>\n

\n
\n Contacts<\/u>
\n <\/strong>
\n
\n Investors<\/strong>
\n
TIBEREND STRATEGIC ADVISORS, INC.
Jonathan Nugent
205-566-3026
jnugent@tiberend.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This virtual investor event will be held on February 25, 2025. Dr. Vera will present an overview of Marker\u2019s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET). Details of the presentation are as follows: \u00a0Event: \u00a0H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference \u00a0Date:\u00a0 \u00a0February 25, 2025, at 3:30 PM ET \u00a0Location: \u00a0Virtual Meeting … <\/p>\n

Continue reading “Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817365","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMarker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This virtual investor event will be held on February 25, 2025. Dr. Vera will present an overview of Marker\u2019s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET). Details of the presentation are as follows: \u00a0Event: \u00a0H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference \u00a0Date:\u00a0 \u00a0February 25, 2025, at 3:30 PM ET \u00a0Location: \u00a0Virtual Meeting … Continue reading "Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T12:26:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference\",\"datePublished\":\"2025-02-25T12:26:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/\"},\"wordCount\":551,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/\",\"name\":\"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=\",\"datePublished\":\"2025-02-25T12:26:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Market Newsdesk","og_description":"HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This virtual investor event will be held on February 25, 2025. Dr. Vera will present an overview of Marker\u2019s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET). Details of the presentation are as follows: \u00a0Event: \u00a0H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference \u00a0Date:\u00a0 \u00a0February 25, 2025, at 3:30 PM ET \u00a0Location: \u00a0Virtual Meeting … Continue reading \"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-25T12:26:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference","datePublished":"2025-02-25T12:26:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/"},"wordCount":551,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/","name":"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=","datePublished":"2025-02-25T12:26:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc3MCM2Nzc2MTg2IzIxODc3MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817365"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817365\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}